MedPath

Lutetium Lu-177

Generic Name
Lutetium Lu-177
Brand Names
Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce)
Drug Type
Small Molecule
Chemical Formula
Lu
CAS Number
14265-75-9
Unique Ingredient Identifier
BRH40Y9V1Q

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

  • Neuroendocrine Tumors

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Lu-177 PSMA Treatment in Cell Renal Carcinoma
2025/05/06
NCT06959433
Phase 3
Not yet recruiting
Ankara University
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
2024/04/23
NCT06379217
Phase 1
Recruiting
Novartis Pharmaceuticals
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
2023/11/07
NCT06121271
Phase 2
Not yet recruiting
University College, London
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
2023/08/14
NCT05987176
Phase 2
Recruiting
Imperial College London
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
2023/04/18
NCT05816720
N/A
Completed
Novartis Pharmaceuticals
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
2023/01/26
NCT05701007
N/A
Completed
Pfizer
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
2022/12/23
NCT05663710
Phase 1
Recruiting
M.D. Anderson Cancer Center
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
2022/11/09
NCT05610826
Phase 1
Withdrawn
University of Chicago
177Lu-HTK03170 in MCRPC with PSMA Positive Disease
2022/10/07
NCT05570994
Phase 1
Suspended
British Columbia Cancer Agency
A clinical study to determine the dose and assess safety and efficacy of radioimmuntherapy in patients with glioblastoma, where Lutetium 177 labelled 6A10 antibody Fab fragments are applied to the tumor resection cavity.
2024/07/10
2024-513638-39-00
Phase 1
Recruiting
Universitaetsklinikum Muenster AöR

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
ENDOLUCINBETA RADIOPHARMACEUTICAL PRECURSOR SOLUTION 40 GBQ/ML
ITM Medical Isotopes GmbH
SIN15971P
SOLUTION
40 GBq/ml
7/3/2020
LUTATHERA SOLUTION FOR INFUSION 370 MBQ/ML
Advanced Accelerator Applications (Italy) s.r.l., Advanced Accelerator Applications Ibérica S.L.U.
SIN15947P
INJECTION, SOLUTION (RADIOPHARMACEUTICAL)
370 Mbq/ml
6/1/2020

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy